Page 51 - JCTR-10-1
P. 51

Gonda et al. | Journal of Clinical and Translational Research 2024; 10(1): 33-51   47
        Supplementary Data 4


                                   Table 3a. Baseline  characteristics  of COVID-19 patients  receiving
                                   molnupiravir plus clarithromycin or molnupiravir alone
                                  Characteristics         Molnupiravir+  Molnupiravir  P‑value
                                                          CAM (n=54)    (n=37)
                                  Female gender            26 (48.1%)  23 (62.2%)  n.s.
                                  Age (years)              78 (49 – 96)  76 (67 – 100)  n.s.
                                  Male gender              28 (51.9%)  14 (37.8%)  n.s.
                                  Age (years)              74 (49 – 91)  73 (64 – 96)  n.s.
                                  Baseline symptoms
                                    Fever                   54 (100%)   0 (0%)   <0.05
                                    Cough and sputa        53 (98.1%)   0 (0%)   <0.05
                                    Fatigue                42 (77.8%)  21 (56.7%)  n.s.
                                    Shortness of breath    36 (66.7%)   0 (0%)   <0.05
                                    Chest tightness        32 (59.2%)   0 (0%)   <0.05
                                    Dyspnea (93% < SpO < 96%)  30 (55.6%)  0 (0%)  <0.05
                                                  2
                                    Nausea                 21 (38.9%)  19 (51.3%)  n.s.
                                    Vomit                  17 (31.5%)  11 (29.7%)  n.s.
                                    Headache                6 (11.1%)  4 (10.8%)  n.s.
                                    Chills                  5 (9.2%)    0 (0%)    n.s.
                                    Diarrhea                3 (5.5%)    2 (5.4%)  n.s.
                                    Hair removal            3 (5.5%)    1 (2.7%)  n.s.
                                    Cingulum                2 (3.7%)    1 (2.7%)  n.s.
                                    Skin rash               2 (3.7%)    2 (5.4%)  n.s.
                                    Conjunctiva inflammation  1 (1.8%)  1 (2.7%)  n.s.
                                    Myalgia                 1 (1.8%)    0 (0%)    n.s.
                                    Abdominal pain          1 (1.8%)    0 (0%)    n.s.
                                    Blood cough             1 (1.8%)    0 (0%)    n.s.
                                    Charlson index         25 (46.2%)  16 (43.2%)  n.s.
                                  Baseline comorbidity
                                    Cardiovascular disease 1  51 (94.4%)  34 (91.9%)  n.s.
                                    Cerebrovascular disease 2  42 (77.8%)  32 (86.5%)  n.s.
                                    Respiratory diseases 3  38 (70.3%)  0 (0%)   <0.05
                                    Orthopedic disease 4   36 (66.7%)  28 (75.7%)  n.s.
                                    Hypertension           32 (59.2%)  26 (70.3%)  n.s.
                                    Diabetes mellitus      28 (51.8%)  15 (40.5%)  n.s.
                                    Cancer 5               17 (31.5%)  13 (35.1%)  n.s.
                                    Chronic renal failure   9 (16.6%)  8 (21.6%)  n.s.
                                  Vaccination             51/54 (94.4%)  35/37 (94.6%)  n.s.
                                    Within 6 months before admission  49/51 (96.1%)  33/35 (94.2%)  n.s.
                                     1 vaccination        47/49 (95.9%)  31/33 (93.9%)  n.s.
                                     2 vaccinations        2/49 (4.0%)  2/33 (6.1%)  n.s.
                                    Within 3 months before admission  2/51 (3.9%)  2/35 (5.7%)  n.s.
                                     1 vaccination          1/2 (50%)  1/2 (50%)  n.s.
                                     2 vaccinations         1/2 (50%)  1/2 (50%)  n.s.
                                   Abbreviations: CAM: Clarithromycin, n.s.: No significant difference.
                                   1 Heart  failure,  myocardial  infarction,  angina  pectoris,  arrhythmia,  dilatation  of  the
                                   myocarditis, dissecting aneurysm of aorta
                                   2 Cerebral infarction, brain hemorrhage, subarachnoid hemorrhage, cerebral aneurysm
                                   3 Chronic obstructive pulmonary disease, chronic bronchitis, chronic interstitial pneumonia,
                                   bronchial asthma
                                   4 Fracture, prosthesis replacement
                                   5 Esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, cholangiocarcinoma,
                                   colorectal  cancer,  lung  cancer,  breast  cancer,  ovarian  cancer,  laryngeal  cancer,  tongue
                                   cancer, meningioma
                                                  DOI: https://doi.org/10.36922/jctr.00075
   46   47   48   49   50   51   52   53   54   55   56